Therapeutic Class
J&J on CGTs: ‘We are disease, not modality-centric’
Therapeutic ClassJ&J on CGTs: ‘We are disease, not modality-centric’J&J on CGTs: ‘We are disease, not modality-centric’
J&J says it remains agnostic to modality type in favor of the end user despite its recent efforts in the cell and gene therapy (CGT) space.